PDF format
JBR-2022-0234-Supplementary Download(19718KB)JBR-2022-0234-Supplementary
Figures of the Article
-
HSP90B1 is an intrinsic predictor for the prognosis of irradiation therapy in GBM patients.
-
HSP90B1 inhibits the sensitivity of GBM cells to radiation therapy.
-
HSP90B1 enhances the glycolytic capacity of GBM cells.
-
HSP90B1 promotes plasma membrane translocation of GLUT1 in GBM cells.
-
HSP90B1 knockdown combined with IR improves the survival of mice bearing GBM.
Related articles
-
2025, 39(2): 146-154. DOI: 10.7555/JBR.37.20230295
-
2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
-
2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
-
2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
-
2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
-
2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
-
Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
-
2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
-
2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
-
2015, 29(1): 61-68. DOI: 10.7555/JBR.29.20130108